Press Release Archive

 
11.25.2021 - Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to <12 Years of Age in the European Union

NEW YORK and MAINZ, Germany, November 25, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine COMIRNATY® in children 5 to under 12 years of age. The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future.

 
11.24.2021 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.

 
11.22.2021 - Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
*/ /*-->*/ /*-->*/
  • Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no
 
11.19.2021 - Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

NEW HAVEN, Conn., and NEW YORK, November 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArgeting Chimera (PROTAC®) protein degrader, will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021.

 
11.19.2021 - Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
*/ /*-->*/ /*-->*/
  • Expanded authorization allows more Americans to receive a booster dose to help preserve a high-level of protection against COVID-19
 
11.18.2021 - Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.

 
11.18.2021 - Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
*/ /*-->*/ /*-->*/
  • If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2
  • Pfizer is se
 
11.17.2021 - Pfizer Completes Acquisition of Trillium Therapeutics
*/ /*-->*/ /*-->*/

Acquisition enhances Pfizer’s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies

 
11.17.2021 - Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
*/ /*-->*/ /*-->*/

Mike McDermott named EVP Chief Global Supply Officer

 
11.16.2021 - Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
*/ /*-->*/ /*-->*/
  •  If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2
  • EUA submission includes clinical data from a
 
11.16.2021 - Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
*/ /*-->*/ /*-->*/
  • Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people, particularly those living in the poorest parts of the world
  • Agreement will enable qualified sub-licensees to supply countries com
 
11.11.2021 - Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana
  • Zipline successfully completes world’s first long-range drone delivery of vaccines requiring ultra-cold-chain

SAN FRANCISCO, NEW YORK and MAINZ, GERMANY, November 11, 2021 – Zipline, the global leader in instant logistics, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that Zipline has successfully completed the first long-range drone delivery of both authorized mRNA COVID-19 vaccines requiring ultra-cold-chain in Ghana.

 
11.10.2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.

 
11.09.2021 - Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
  • Rimegepant, commercialized as Nurtec® ODT in the U.S., is the first and only oral CGRP (calcitonin gene- related peptide) receptor antagonist for the acute and preventive treatment of migraine
  • Biohaven to receive tiered double-digit royalties on ex-U.S. net sales as well as upfront and milestone payments of up to $1.24 billion
  • Biohaven and Pfizer global collaboration to be discussed on Biohaven 3Q Earnings Investor Call 8:00AM ET today

NEW HAVEN, Conn., and NEW YORK, November 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

 
11.05.2021 - Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
*/ /*-->*/ /*-->*/
  • PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19
  • In the overall study population through Day 28, no deaths
 
11.02.2021 - PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
*/
 
10.29.2021 - Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
*/ /*-->*/ /*-->*/
  • Emergency Use Authorization (EUA) is supported by clinical data showing a favorable safety profile an
 
10.28.2021 - Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
*/ /*-->*/ /*-->*/

Doses expected to be delivered by April 2022

 
10.26.2021 - FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
*/ /*-->*/ /*-->*/
  • Committee reviewed clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 to <12 yea
 
10.21.2021 - Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
*/ /*-->*/ /*-->*/
  • First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against dis

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Online Pfizer Press Kit